ClinicalTrials.gg
RecruitingNCT06966024Updated Aug 18, 2026

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

A Phase 1 interventional study of DCC-2812 in Renal Cell Carcinoma, Urothelial Carcinoma and Castration-resistant Prostate Cancer, sponsored by Deciphera Pharmaceuticals, LLC. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,144 studies in Carcinoma, Renal Cell with a site in United States — 155 open to participants now, 279 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Planned enrollment
375th of 1,010
60 · median 40
Started
2025
with 38 others
Phase 1
342 of 1,144
38 open now
Primary completion
2029-02
later than 226 of 277 live
Registered
1,084th of 1,144
by date

Among the 1,144 studies in Carcinoma, Renal Cell with a site in United States, this one is the 375th largest by planned enrollment of the 1,010 interventional ones that give a count, is one of 39 that started in 2025, is one of 342 in phase 1, reaches primary completion later than 226 of the 277 other live ones, and was the 1,084th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

155 of the 1,144 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

150 more — sign in →

All 155 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,144 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

03

Conditions studied

  • Renal Cell Carcinoma
  • Urothelial Carcinoma
  • Castration-resistant Prostate Cancer

Keywords

  • Advanced malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have confirmed Advanced or Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
  • Able to take oral medication
  • If a female is of , must have a negative pregnancy test prior to enrollment and all participants agree to follow the requirements
  • Adequate organ function and electrolytes

Key Exclusion Criteria:

  • Received any prior anticancer therapy or any therapy within a specified timeframe prior to first dose of DCC-2812
  • Impaired cardiac function
  • Major surgery within 28 days of the first dose of study drug
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    DCC-2812

    Participants will receive DCC-2812 in dose escalation manner per dosing regimen depending upon evolving pharmacokinetic (PK), pharmacodynamic, and safety data.

    Drug: DCC-2812

Interventions

  • DrugDCC-2812

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose-limiting Toxicities (DLTs)

    Time frame: Cycle 1 (28 days)

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 42 months

  3. Number of Participants With Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs

    Time frame: Up to 42 months

Secondary outcomes

  1. Radiographic Objective Response Rate (rORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to 42 months

  2. Radiographic Duration of Response (rDOR) per RECIST v1.1

    Time frame: Up to 42 months

  3. PK: Maximum Observed Plasma Drug Concentration (Cmax)

    Time frame: Predose up to 24 hours postdose (up to 42 months)

  4. PK: Time to Reach Cmax (Tmax)

    Time frame: Predose up to 24 hours postdose (up to 42 months)

  5. PK: Area Under the Plasma Concentration-time Curve (AUC)

    Time frame: Predose up to 24 hours postdose (up to 42 months)

  6. PK: Trough Plasma Concentration (Ctrough)

    Time frame: Predose up to 24 hours postdose (up to 42 months)

07

Study locations

8 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2029, 42 months after the start.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 42 months is below that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 11, 2025
StartActual
Aug 27, 2025
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06966024
Responsible party
Sponsor
First posted
May 11, 2025
Start date
Aug 27, 2025
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Aug 18, 2026

Study contacts

Clinical Team
Contact
clinicaltrials@deciphera.com
888-724-3274
Clinical Team
study director · Deciphera Pharmaceuticals, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion